Trials / Completed
CompletedNCT00546494
Study Evaluating Effexor® (Venlafaxine) in Achieving Response and Maintaining Remission
A Study Of The Utility Of Effexor® (Venlafaxine) In Achieving Response And Maintaining Remission Among Taiwanese Patients With Depression
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 350 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a study to determine the utility of Effexor® (venlafaxine) in achieving response, including time to response, maintaining remission, and time to remission as measured by the 17-item Hamilton Rating Scale for Depression (HAM-D) and to determine the utility of Effexor® (venlafxine) on the various cluster of symptom scales in the 17-item HAM-D.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Effexor® (Venlafaxine) |
Timeline
- Start date
- 2004-02-01
- Completion
- 2005-03-01
- First posted
- 2007-10-19
- Last updated
- 2007-10-19
Source: ClinicalTrials.gov record NCT00546494. Inclusion in this directory is not an endorsement.